Cmax depends on how much drug reaches the circulation, how quickly it is absorbed, and how widely it distributes. Dose, absorption rate, and bioavailability therefore influence the magnitude of the peak. Comparing Cmax values can help distinguish changes in drug exposure caused by the administered amount from those associated with absorption or availability.
Cmin reflects the concentration remaining when the next dose is due, so drug elimination and the length of the dosing interval are especially important. More frequent dosing changes the time available for concentrations to decline, while slower elimination can preserve higher trough values. These relationships make Cmin useful when evaluating whether a regimen sustains adequate exposure.
Cmax emphasizes the highest observed concentration, whereas Cmin shows the residual concentration at the end of the dosing interval. Considering both values gives a broader view than either measure alone: the peak helps assess exposure associated with concentration-related toxicity, while the trough supports evaluation of sustained exposure and potential therapeutic effectiveness.
Differences in Cmax and Cmin may indicate that patients or dosing regimens produce different exposure patterns. A regimen can generate a higher peak, a different trough, or both, even when comparisons involve the same general treatment. Reviewing these measures together supports interpretation of variability, assessment of therapeutic response, and identification of concentration-related safety concerns.
Therapeutic drug monitoring uses measured drug concentrations to relate an individual patient's exposure to treatment goals and safety concerns. Assessing the peak and the pre-dose trough provides complementary information for dose optimization. Clinicians and researchers can use these results to compare observed concentrations with the exposure pattern expected from a selected regimen and consider whether adjustment is warranted.
Clinical researchers compare Cmax and Cmin across dosing regimens to characterize exposure, evaluate efficacy, and assess the risk of concentration-related toxicity. These comparisons can inform dose optimization and contribute to the design of treatments that balance therapeutic benefit with safety. The measures also provide pharmacokinetic context for interpreting how dosing choices affect blood or plasma concentrations.